Pharmaceutical and biomedical organizations face significant insider risk challenges due to the need to protect highly valuable intellectual property such as personally identifiable information, drug formulations, and clinical trial data. Large networks of employees, contractors, and third‑party collaborators regularly access, store, and share sensitive information, increasing complexity and exposure. CISOs must balance open collaboration essential for research and development with strict data protection requirements. At the same time, companies must navigate a highly regulated environment and comply with multiple data protection laws and standards. Effective insider risk management is critical to safeguarding innovation, maintaining compliance, and protecting patient and business trust.

Join for free to read